Amedisys (NASDAQ:AMED) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Amedisys (NASDAQ:AMED – Get Free Report) in a report issued on Monday. The firm set a “buy” rating on the health services provider’s stock.

Separately, Cantor Fitzgerald increased their target price on Amedisys from $100.00 to $101.00 and gave the stock a “neutral” rating in a research note on Thursday, September 14th. Nine investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Amedisys presently has a consensus rating of “Hold” and a consensus target price of $103.55.

View Our Latest Analysis on AMED

Amedisys Stock Performance

Shares of AMED stock opened at $94.55 on Monday. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.00 and a quick ratio of 1.00. The stock has a market cap of $3.09 billion, a PE ratio of 1,350.71, a price-to-earnings-growth ratio of 2.60 and a beta of 0.92. The stock has a 50-day moving average of $93.10 and a 200-day moving average of $92.36. Amedisys has a one year low of $69.36 and a one year high of $106.01.

Amedisys (NASDAQ:AMED – Get Free Report) last announced its quarterly earnings results on Tuesday, October 24th. The health services provider reported $0.98 EPS for the quarter, missing analysts’ consensus estimates of $1.08 by ($0.10). Amedisys had a net margin of 0.12% and a return on equity of 13.45%. The company had revenue of $556.24 million during the quarter, compared to the consensus estimate of $560.23 million. During the same period last year, the company earned $1.15 earnings per share. The business’s revenue was down .3% compared to the same quarter last year. As a group, sell-side analysts expect that Amedisys will post 4.41 earnings per share for the current year.

Institutional Investors Weigh In On Amedisys

Several large investors have recently made changes to their positions in AMED. Pinebridge Investments L.P. bought a new stake in Amedisys in the 2nd quarter valued at $26,000. Neo Ivy Capital Management bought a new stake in Amedisys in the 2nd quarter valued at $44,000. Headlands Technologies LLC bought a new stake in Amedisys in the 2nd quarter valued at $46,000. Covestor Ltd raised its stake in Amedisys by 88.9% in the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock valued at $56,000 after acquiring an additional 152 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in Amedisys in the 1st quarter valued at $67,000. Institutional investors and hedge funds own 95.70% of the company’s stock.

About Amedisys (Get Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

You may also like

Research shows that grandparents are great personal finance teachers. Here’s what my poppa who became an accountant during the Great Depression tried to teach me about money

Curious workers are seen as insubordinate and annoy managers, HBR research shows

PDD (NASDAQ:PDD) Price Target Raised to $190.00 at Benchmark